Nuvectis Pharma, Inc.: insider trades · United States · SEC (Form 4)

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. (ticker: NVCT) is a U.S.-based clinical-stage biopharmaceutical company listed on the NASDAQ in the United States. The company operates in precision oncology, a therapeutic segment that seeks to match treatments to specific biological drivers and biomarker-defined patient populations rather than using one-size-fits-all cancer therapy. Nuvectis was incorporated in Delaware in July 2020 under the name Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Its principal executive offices are in Fort Lee, New Jersey, giving the company a clearly U.S.-centric operating base.([sec.gov](https://www.sec.gov/Archives/edgar/data/1875558/000155837025001496/tmb-20241231x10k.htm?utm_source=openai)) The company’s business model is built around the discovery, acquisition, and clinical development of proprietary drug candidates aimed at serious diseases with significant unmet medical need. Nuvectis currently has two clinical assets at the center of its pipeline. NXP900 is an oral small-molecule inhibitor of SRC Family Kinases, including SRC and YES1. The asset is designed as a type 1.5 inhibitor, with the goal of shutting down both catalytic and scaffolding functions of SRC signaling. According to company disclosures, NXP900 has completed a dose-escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers, supporting a phase 1b program in monotherapy and in combination with other anticancer agents. NXP800 is an oral small molecule that activates GCN2 kinase; it has shown biological activity in a phase 1b study in platinum-resistant, ARID1A-mutated ovarian cancer, and the company continues to evaluate additional development opportunities, including cholangiocarcinoma through an investigator-sponsored trial at Mayo Clinic.([nuvectis.com](https://nuvectis.com/nxp900/?utm_source=openai)) From a competitive standpoint, Nuvectis is still a pure-play small-cap biotech with no marketed products, which makes it highly dependent on clinical execution, financing capacity, and the probability of advancing one or both programs into later-stage development. Its differentiating features are the precision-medicine focus and a management team with prior experience taking oncology assets through approval and commercial launch at other biopharma companies. The company has also highlighted future development paths in non-small cell lung cancer, including potential combination strategies with EGFR and ALK inhibitors to address resistance mechanisms, as well as biomarker-selected solid tumors.([nuvectis.com](https://nuvectis.com/about-us/?utm_source=openai)) Recent developments point to continued momentum around NXP900. In 2025 and 2026, Nuvectis reported ongoing phase 1b work, safety and PK/PD disclosures, and scientific presentations at major conferences such as AACR and ENA. The company also hosted a December 2025 KOL event focused on the NXP900 phase 1b program, underscoring that this asset remains the key near-term value driver for the company.([nuvectis.com](https://nuvectis.com/nxp900-publications/?utm_source=openai))